LONGMONT, Colo., Dec. 2 /PRNewswire/ -- MicroPhage, Inc., http://www.microphage.com, announced today that Lynn M. Taussig, MD has joined the company’s Board of Directors. Taussig was president and CEO of National Jewish Medical and Research Center in Denver, the nation’s leading institution for studying respiratory diseases, from 1993 to 2006. His medical specialty is pediatric pulmonology.
“I have followed MicroPhage extensively and am impressed with its progress in developing new, rapid bacterial identification and antibiotic susceptibility tests, and am enthused about the clinical impact their products will have in providing accurate and cost-effective diagnosis of serious infections,” said Taussig.
MicroPhage CEO Steve Lundy knows Taussig’s expertise in diagnosis and management of respiratory diseases and his healthcare management experience will be valuable to the board in guiding the company’s future. “We are pleased to have a physician and hospital executive of Dr. Taussig’s stature join our board. His involvement and support shows confidence in MicroPhage, and his clinical expertise and vision will be deeply valued,” said Lundy.
Taussig has served on numerous academic, government and business boards and commissions and has authored more than 170 publications related to respiratory illnesses in children. He has earned several academic, civic and professional honors, including the Distinguished Achievement Award from the American Thoracic Society. He currently serves as special advisor to the Provost for Life Sciences at the University of Denver and is on the Board of Directors of the Colorado Biosciences Association.
MicroPhage is in late stage development for its bacterial detection and susceptibility diagnostic system. The first products are targeted for rapid detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive Staphylococcus aureus) for screening and diagnostic applications.
About MicroPhage
Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its bacteriophage-based amplification platform for immunoassay diagnostics, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive bacterial identification and antibiotic susceptibility testing. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testing, and are designed to fit the demands for improving laboratory workflow. For further information, go to http://www.microphage.com.
CONTACT: Steve Lundy of MicroPhage, +1-303-339-1412, slundy@microphage.com
Web site: http://www.microphage.com/
